RxDoctor Payments Data

Richard Weinstein, MD

Cardiovascular Disease · Rockville, MDNPI 1073549077

Payments from drug & device makers

$4,451in general payments, 2019–2025

Across 251 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$696
  • Amgen$618
  • Novartis$456
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$348
  • Boehringer Ingelheim$326
  • AstraZeneca$308
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,445100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,451 in reported general payments places this provider in the 65th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$406,441
Medicare patients
2,020
Services billed
5,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban552$685,223
EntrestoSacubitril/Valsartan118$158,304
JardianceEmpagliflozin138$118,381
XareltoRivaroxaban96$104,021
FarxigaDapagliflozin Propanediol66$50,074
Repatha SureclickEvolocumab33$37,990
VascepaIcosapent Ethyl24$20,097
Metoprolol Succinate553$12,081
Rosuvastatin Calcium362$11,889
Dabigatran EtexilateDabigatran Etexilate Mesylate26$8,893
Atorvastatin Calcium612$8,784
Ezetimibe93$4,791
Lisinopril458$4,244
Flecainide Acetate67$3,967
Irbesartan96$3,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$259$685,223552 claims
NovartisEntresto$456$158,304118 claims
Boehringer IngelheimJardiance, Pradaxa$326$121,523152 claims
Johnson & JohnsonXarelto$78$104,02196 claims
AstraZenecaFarxiga$308$50,07466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →